Literature DB >> 17891656

Quality of life among heroin users on buprenorphine versus methadone maintenance.

Alexander M Ponizovsky1, Alexander Grinshpoon.   

Abstract

OBJECTIVES: To assess the quality of life (QoL) of heroin users starting and following 4 and 8 months of maintenance treatment program using buprenorphine vs. methadone.
METHODS: Participants received maintenance treatment with oral methadone or sublingual buprenorphine for the treatment of heroin dependence. Participants' QoL was measured using the Quality of Life Enjoyment and Satisfaction Questionnaire completed before treatment and at 1-, 4-, and 8-month follow-up. Baseline data from 304 heroin-dependent participants starting maintenance treatment, and 4-month and 8-month follow-up data for the 180 and 129 participants, respectively, retained in trial treatment are presented.
RESULTS: For the participants retained in treatment, statistically significant improvements in QoL and all specific life domains were observed in 4 and 8 months. However, for users who were maintained on methadone, this improvement was observed during the first month of treatment.
CONCLUSIONS: The results show the beneficial effects of the maintenance treatment programs using both buprenorphine and methadone with regard to satisfaction with QoL and all specific life domains among heroin-dependent outpatients, with methadone having an earlier onset than buprenorphine. Further studies are needed to identify the factors linked to these benefits and their time course.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17891656     DOI: 10.1080/00952990701523698

Source DB:  PubMed          Journal:  Am J Drug Alcohol Abuse        ISSN: 0095-2990            Impact factor:   3.829


  33 in total

1.  Patient perspectives on buprenorphine/naloxone: a qualitative study of retention during the starting treatment with agonist replacement therapies (START) study.

Authors:  Cheryl Teruya; Robert P Schwartz; Shannon Gwin Mitchell; Albert L Hasson; Christie Thomas; Samantha H Buoncristiani; Yih-Ing Hser; Katharina Wiest; Allan J Cohen; Naomi Glick; Petra Jacobs; Paul McLaughlin; Walter Ling
Journal:  J Psychoactive Drugs       Date:  2014 Nov-Dec

Review 2.  Quality of life as an outcome of opioid use disorder treatment: A systematic review.

Authors:  Jeremy W Bray; Brandon Aden; Ashley A Eggman; Leah Hellerstein; Eve Wittenberg; Bohdan Nosyk; Judy C Stribling; Bruce R Schackman
Journal:  J Subst Abuse Treat       Date:  2017-02-10

3.  Short term health-related quality of life improvement during opioid agonist treatment.

Authors:  B Nosyk; J W Bray; E Wittenberg; B Aden; A A Eggman; R D Weiss; J Potter; A Ang; Y-I Hser; W Ling; B R Schackman
Journal:  Drug Alcohol Depend       Date:  2015-10-25       Impact factor: 4.492

4.  Health-related quality of life changes associated with buprenorphine treatment for opioid dependence.

Authors:  Dennis W Raisch; Heather M Campbell; David A Garnand; Mark A Jones; Mike R Sather; Rupali Naik; Walter Ling
Journal:  Qual Life Res       Date:  2011-10-11       Impact factor: 4.147

5.  Beyond drug use: a systematic consideration of other outcomes in evaluations of treatments for substance use disorders.

Authors:  Stephen T Tiffany; Lawrence Friedman; Shelly F Greenfield; Deborah S Hasin; Ron Jackson
Journal:  Addiction       Date:  2011-10-07       Impact factor: 6.526

6.  Patient Perspectives Associated with Intended Duration of Buprenorphine Maintenance Therapy.

Authors:  Brandon S Bentzley; Kelly S Barth; Sudie E Back; Garrett Aronson; Sarah W Book
Journal:  J Subst Abuse Treat       Date:  2015-04-07

7.  Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics.

Authors:  P Todd Korthuis; Mary Jo Tozzi; Vijay Nandi; David A Fiellin; Linda Weiss; James E Egan; Michael Botsko; Angela Acosta; Marc N Gourevitch; David Hersh; Jeffrey Hsu; Joshua Boverman; Frederick L Altice
Journal:  J Acquir Immune Defic Syndr       Date:  2011-03-01       Impact factor: 3.731

8.  Predictors of early dropout in outpatient buprenorphine/naloxone treatment.

Authors:  David E Marcovitz; R Kathryn McHugh; Julie Volpe; Victoria Votaw; Hilary S Connery
Journal:  Am J Addict       Date:  2016-07-21

9.  Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic.

Authors:  Gerald Cochran; Julie Bruneau; Nicholas Cox; Adam J Gordon
Journal:  Subst Abus       Date:  2020       Impact factor: 3.716

10.  Characterizing Long-Term Health Related Quality of Life Trajectories of Individuals With Opioid Use Disorder.

Authors:  Emanuel Krebs; Thomas Kerr; Evan Wood; Bohdan Nosyk
Journal:  J Subst Abuse Treat       Date:  2016-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.